LEMTRADA (alemtuzumab), selective immunosuppressant

• LEMTRADA has a Marketing Authorisation in adults with an active form of relapsing-remitting multiple sclerosis (RRMS), defined by clinical parameters or MRI of patients included in phase III studies, disease-modifying treatment-naïve patients or patients previously treated with at least one relapse in the year prior to inclusion or at least two in the 2 years prior to inclusion.
• Given the serious adverse effects of the product with a significant residual effect and medium-term potential risks of its administration, its hospital use has been restricted.
• LEMTRADA is reserved for severe forms of RRMS.
• No comparison versus a treatment indicated in these highly active or rapidly progressing forms has been carried out.

-